Stocks Health care TSHA
NASDAQ · Health careTaysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. brought in $5.5M of revenue over the twelve months to June 30, 2026, down 32.3% from a year earlier. It posted a net loss of $149.6M. In fiscal 2025 capital spending exceeded operating cash flow by $93.8M. At June 30, 2026 it held $455.4M in cash against $49.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Taysha Gene Therapies, Inc.
- Net worth
- Taysha Gene Therapies, Inc. has a market value (market cap) of $1.4B at the latest share price, and shareholders' equity of $387.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $9.8M (+17.3% year on year), with a net loss of $109M. Over the 12 months to June 30, 2026: revenue $5.5M, net loss $149.6M.
- Cash flow
- In fiscal 2025 operations used $93.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Taysha Gene Therapies, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
What Taysha Gene Therapies, Inc. does
Taysha Gene Therapies, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TSHA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9.8M | -$109M | -$0.34 | -$93.8M |
| 2024 | $8.3M | -$89.3M | -$0.36 | -$81.6M |
| 2023 | $15.5M | -$111.6M | -$0.96 | -$76.9M |
| 2022 | $2.5M | -$166M | -$3.78 | -$109M |
| 2021 | n/a | -$174.5M | -$4.64 | -$132.3M |
| 2020 | n/a | -$60M | -$3.40 | -$30.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TSHA ranks in Health care
Latest SEC filings
What Taysha Gene Therapies, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- June 25, 2026
- June 22, 2026
- June 2, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 6, 2026
Insider trades
What the people running Taysha Gene Therapies, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 10, 2026 | Nagendran SukumarPresident and Head of R&D, Director | Soldpre-planned (10b5-1) | 200,000 | $1.2M |
| June 1, 2026 | Donenberg Phillip B.Director | Received as pay | 21,335 | - |
| June 1, 2026 | Stalfort John A IIIDirector | Received as pay | 21,335 | - |
| June 1, 2026 | Sepp-Lorenzino LauraDirector | Received as pay | 21,335 | - |
| June 1, 2026 | Long Alison SDirector | Received as pay | 21,335 | - |
| April 10, 2026 | Nagendran SukumarPresident and Head of R&D, Director | Exercised options | 19,021 | $32.5K |
| April 10, 2026 | Nagendran SukumarPresident and Head of R&D, Director | Soldpre-planned (10b5-1) | 200,000 | $892K |
| February 4, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sold | 1,655 | $7.5K |
Who owns TSHA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 9.99% | November 14, 2024 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| Paul B Manning13D, may seek influence with 5 related filers | 9.8% | June 3, 2025 |
| RTW Investments, LP13G, passive with 1 related filers | 7% | May 15, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 6.3% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 209 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Avoro Capital Advisors LLC | 23,888,888 | +2,188,888 |
| RA Capital Management, L.P. | 23,555,648 | 0 |
| Goldman Sachs Group Inc | 22,713,118 | +343,473 |
| BlackRock, Inc. | 20,691,927 | +2,326,319 |
| Vestal Point Capital, LP | 19,415,000 | +1,415,000 |
| Morgan Stanley | 16,487,479 | -1,477,892 |
| Rtw Investments, LP | 13,560,258 | -119,990 |
| Fmr LLC | 13,336,413 | -984,842 |
| Vanguard Capital Management LLC | 12,478,595 | +2,247,093 |
| State Street Corp | 11,421,920 | +212,842 |
| Siren, L.L.C. | 9,846,579 | +1,016,666 |
| Octagon Capital Advisors LP | 9,693,244 | +833,333 |
| Geode Capital Management, LLC | 6,560,394 | +1,028,439 |
| Polar Capital Holdings Plc | 5,117,133 | -537,207 |
| Mpm Bioimpact LLC | 4,500,000 | new |
| D. E. Shaw & Co., Inc. | 4,398,652 | -28,649 |
| Baker Bros. Advisors LP | 4,004,756 | 0 |
| Wellington Management Group Llp | 3,975,605 | +3,349,244 |
| Healthcare of Ontario Pension Plan Trust Fund | 3,885,501 | +1,002,200 |
| GordonMD Global Investments LP | 723,185 | -14,365 |
Insiders
7 insiders reported holding 6,959,002 shares in total, about $29.7M at the last price.
| Holder | Shares |
|---|---|
| Nolan Sean P.Chief Executive Officer, Director | 2,908,257 |
| Alam KamranCHIEF FINANCIAL OFFICER | 1,442,131 |
| Stalfort John A IIIDirector | 1,176,559 |
| Nagendran SukumarPresident and Head of R&D, Director | 936,410 |
| Donenberg Phillip B.Director | 241,289 |
| Sepp-Lorenzino LauraDirector | 127,178 |
| Long Alison SDirector | 127,178 |
Questions about TSHA
What does Taysha Gene Therapies, Inc. do?
Taysha Gene Therapies, Inc. is a company in the Health care sector, listed on NASDAQ as TSHA. Its shares trade on NASDAQ under the ticker TSHA.
What is Taysha Gene Therapies, Inc.'s net worth?
Taysha Gene Therapies, Inc. has a market value (market cap) of $1.4B at the latest share price, and shareholders' equity of $387.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Taysha Gene Therapies, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $149.6M on revenue of $5.5M.
How much revenue does Taysha Gene Therapies, Inc. make?
Over the twelve months to June 30, 2026 Taysha Gene Therapies, Inc. reported revenue of $5.5M. That is 32.3% less than a year earlier.
When did Taysha Gene Therapies, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.
When is Taysha Gene Therapies, Inc.'s next earnings report?
Taysha Gene Therapies, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare TSHA with
Follow TSHA
Get an email when Taysha Gene Therapies, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Taysha Gene Therapies, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.